Form 4: Passage Bio CEO William Chou Acquires 575,000 Stock Options
SEC Form 4 Filing
William Chou, President and CEO of Passage Bio, Inc., acquired 575,000 employee stock options on March 15, 2024.
Summary
- William Chou, the President and CEO of Passage Bio, Inc., filed a Form 4 on March 19, 2024, reporting a transaction.
- On March 15, 2024, Chou acquired 575,000 employee stock options with an exercise price of $1.50.
- The options vest monthly, starting April 15, 2024, over a period of 48 months, contingent upon Chou's continued service to the company.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing related to stock option grants, which is neither particularly positive nor negative. It's a routine disclosure.
Future Outlook
The stock options vest over a 48-month period, contingent on the CEO's continued service, aligning his interests with the company's long-term performance.
Industry Context
Form 4 filings are standard practice and provide transparency into the transactions of company insiders, allowing investors to monitor executive compensation and potential alignment with shareholder interests.
Stakeholder Impact
- The stock option grant aligns the CEO's interests with those of the shareholders, incentivizing him to increase the company's value.
Key Dates
| Date | Description |
|---|---|
| 03/15/2024 | Date of the stock option acquisition. |
| 04/15/2024 | Start date for monthly vesting of the stock options. |
| 03/19/2024 | Date the Form 4 was filed. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.